{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:22:00Z","timestamp":1788322920404,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:37:05Z","timestamp":1749091025000},"page":"775-787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions | Late\/Deferred ASCT in Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Clifton C.","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-0061","authenticated-orcid":false,"given":"Monique A.","family":"Hartley-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2025.06.003_bib0001","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.clml.2025.06.003_bib0002","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.clml.2025.06.003_bib0003","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0004","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph","year":"2024","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.clml.2025.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2025.06.003_bib0006","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S2152-2650(24)02344-9","article-title":"OA-63 Daratumumab + Bortezomib\/Lenalidomide\/Dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: results of the phase 3 CEPHEUS study","volume":"24","author":"Usmani","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0007","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0008","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","author":"Snowden","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.003_bib0009","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.003_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0011","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.06.003_bib0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0014","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2025.06.003_bib0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2025.06.003_bib0016","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.003_bib0017","first-page":"1","article-title":"Role of autologous transplant in newly diagnosed multiple myeloma patients treated with novel triplets: a systematic review and meta-analysis","author":"Amitai","year":"2024","journal-title":"Acta Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0018","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2022-162741","volume":"140","author":"Hassoun","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0019","first-page":"4762","volume":"142","author":"Zonder","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.003_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1195572","article-title":"The roles of inflammasomes in cancer","volume":"14","author":"Deng","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0021","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2025.06.003_bib0023","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.06.003_bib0024","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.06.003_bib0026","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.clml.2025.06.003_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2025.06.003_bib0028","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.003_bib0029","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.06.003_bib0031","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.003_bib0032","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0033","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"S1","key":"10.1016\/j.clml.2025.06.003_bib0034","first-page":"218","article-title":"Isatuximab, lenalidomide, bortezomib and dexamethasone for newly-diagnosed, transplant-eligible multiple myeloma: post transplantation interim analysis of the randomized phase III GMMG-HD7 trial","volume":"8","author":"Raab","year":"2024","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized Iskia trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.06.003_bib0036","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2023.41.16_suppl.8000","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction response and MRD results from an open-label randomized phase 3 study","volume":"41","author":"Knop","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.003_bib0037","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0038","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2023-179866","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0039","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood-2024-193308","volume":"144","author":"Goldschmidt","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0040","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood-2024-194768","article-title":"Impact of minimal residual disease on progression-free survival in patients with newly diagnosed multiple myeloma treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone induction therapy in the phase 3 GMMG-HD7 trial","volume":"144","author":"Mai","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0041","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2024-200871","volume":"144","author":"Zweegman","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.06.003_bib0042","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0043","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0044","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1182\/blood-2023-178533","volume":"142","author":"Beksac","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.06.003_bib0045","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0046","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial","volume":"11","author":"O'Donnell","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0047","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.06.003_bib0048","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.003_bib0049","article-title":"MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma","author":"Bhutani","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0051","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","article-title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.06.003_bib0052","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: A phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.06.003_bib0053","doi-asserted-by":"crossref","unstructured":"Derman BA, Kubicki T, Simmons H, et al. Early peripheral blood minimal residual disease status by NGS in patients with newly diagnosed multiple myeloma (MM) on a phase 2 trial receiving elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd). Blood. 2023;142(Suppl 1):1982. doi:10.1182\/blood-2023-182410","DOI":"10.1182\/blood-2023-182410"},{"issue":"7","key":"10.1016\/j.clml.2025.06.003_bib0054","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","article-title":"Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation","volume":"37","author":"Ocio","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0055","doi-asserted-by":"crossref","first-page":"e829","DOI":"10.1097\/HS9.0000000000000829","article-title":"Phase 1b study of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients","volume":"7","author":"Ocio","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0056","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2024-200135","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma (NDMM) not eligible or with No immediate intent for transplant: long-term efficacy and safety in a phase 1b study","volume":"144","author":"Ocio","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0057","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1182\/blood-2024-201768","article-title":"Outcomes of patients by high-risk cytogenetic abnormalities in a phase II study of Isatuximab, weekly carfilzomib, lenalidomide, dexamethasone in newly diagnosed, multiple myeloma (The SKylaRk Trial) who deferred transplant","volume":"144","author":"O'Donnell","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0058","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1182\/blood-2022-156730","article-title":"Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and autologous transplantation: extended follow up of the Master trial","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.06.003_bib0059","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.06.003_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"Evidence meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0061","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.06.003_bib0062","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: A pooled analysis of individual patient data from multiple randomized trials","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.003_bib0063","unstructured":"i2TEAMM. I2TEAMM Presentation to support MRD as accelerated approval endpoint: April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee. US Food & Drug Administration; 2024. Accessed: November 19, 2024, Available at: https:\/\/www.fda.gov\/media\/177738\/download."},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0064","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","volume":"10","author":"Yong","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0065","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: A meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0066","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11912-024-01537-2","article-title":"Minimal residual disease-adapted therapy in multiple myeloma: current evidence and opinions","volume":"26","author":"Meseha","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2025.06.003_bib0067","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S2152-2650(24)01895-0","article-title":"OA-54 efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study","volume":"24","author":"Perrot","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0068","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1182\/blood-2023-186834","article-title":"Advance multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients","volume":"142","author":"Landgren","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0069","doi-asserted-by":"crossref","first-page":"2000.1","DOI":"10.1182\/blood-2024-200210","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)- Master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.003_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1455464","article-title":"Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed\/refractory multiple myeloma","volume":"14","author":"Hamadeh","year":"2024","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0071","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2024-212135","article-title":"Previous HDM\/ASCT adversely impacts PFS with BCMA-directed CAR T-cell therapy in multiple myeloma","volume":"144","author":"Gustine","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0072","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"61","author":"Roussel","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.clml.2025.06.003_bib0073","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0074","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.clml.2025.06.003_bib0075","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0076","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ejh.13650","article-title":"Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma","volume":"107","author":"Jonsdottir","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.003_bib0077","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-020-00400-4","article-title":"Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients","volume":"11","author":"Rosenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10_suppl","key":"10.1016\/j.clml.2025.06.003_bib0078","first-page":"O115","article-title":"Outcomes in African-American (AA) and white patients with newly diagnosed multiple myeloma receiving RVd-alone vs RVd\u2009+\u2009ASCT in DETERMINATION: efficacy, safety, and second primary malignancies (SPMS)","volume":"59","author":"Richardson","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.clml.2025.06.003_bib0079","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume":"141","author":"Diamond","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.06.003_bib0080","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.2022019510","article-title":"Mutation signatures reveal clonal evolution","volume":"141","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0081","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive characterization of prolonged unexplained cytopenias in relapsed\/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.06.003_bib0082","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.06.003_bib0083","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-022-00640-6","article-title":"Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands","volume":"12","author":"Brink","year":"2022","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.clml.2025.06.003_bib0084","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/cncr.32941","article-title":"Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A bone marrow transplantation survivor study","volume":"126","author":"Arora","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jtct.2023.02.011","article-title":"Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma","volume":"29","author":"Chakraborty","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.06.003_bib0086","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","author":"Puig","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.06.003_bib0087","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1200\/JCO.23.00934","article-title":"Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival","volume":"42","author":"Pasquini","year":"2024","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.06.003_bib0088","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma","volume":"4","author":"Martinez-Lopez","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0089","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063037","article-title":"Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial","volume":"12","author":"Royle","year":"2022","journal-title":"BMJ Open"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.06.003_bib0090","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"DVRd followed by Ciltacabtagene Autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine\/CARTITUDE-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"},{"issue":"16_Suppl","key":"10.1016\/j.clml.2025.06.003_bib0091","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.06.003_bib0092","doi-asserted-by":"crossref","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: an open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)","volume":"41","author":"Grosicki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0093","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0094","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41409-021-01371-1","article-title":"Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.clml.2025.06.003_bib0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184706","article-title":"Carfilzomib, Lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma","volume":"13","author":"Baertsch","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2025.06.003_bib0096","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.003_bib0097","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0098","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.003_bib0099","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.06.003_bib0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.06.003_bib0101","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.clml.2025.06.003_bib0102","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2025.06.003_bib0103","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0104","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.06.003_bib0105","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.003_bib0106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/hemato5020012","article-title":"The role of autologous stem cell transplantation in the treatment of newly diagnosed multiple myeloma: is it time to rethink the paradigm in the era of targeted therapy?","volume":"5","author":"Richardson","year":"2024","journal-title":"Hemato"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:38:28Z","timestamp":1776397108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":106,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025002113"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Late\/Deferred ASCT in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}